about
A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKLProtective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis.Paget's disease of bone: an osteoimmunological disorder?Osteoprotegerin in bone metastases: mathematical solution to the puzzleNoncoding RNAs: Possible Players in the Development of FluorosisSynergistic effects of green tea polyphenols and alphacalcidol on chronic inflammation-induced bone loss in female ratsChinese Herbal Formula Huo-Luo-Xiao-Ling Dan Protects against Bone Damage in Adjuvant Arthritis by Modulating the Mediators of Bone RemodelingOsteoporosis: the current status of mesenchymal stem cell-based therapy.Prolactin blocks the expression of receptor activator of nuclear factor κB ligand and reduces osteoclastogenesis and bone loss in murine inflammatory arthritis.Activation of the transcription factor, nuclear factor kappa-B, during the estrous cycle and early pregnancy in the pig.The emerging field of osteoimmunologyEffects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritisGeneration and culture of osteoclasts.Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications.Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.Long term high intensity exercise and damage of small joints in rheumatoid arthritisOsteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary ReportChanges in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.Pathophysiology of Hemophilic Arthropathy.Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice.Genetic susceptibility to hip arthroplasty failure--association with the RANK/OPG pathwayRegulation of RANKL by biomechanical loading in fibrochondrocytes of meniscusThe sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6Increased receptor activator of nuclear factor κβ ligand/osteoprotegerin ratio exacerbates cartilage destruction in osteoarthritis in vitroB Cell IgD Deletion Prevents Alveolar Bone Loss Following Murine Oral Infection.Activation of human fibroblast-like synoviocytes by uric acid crystals in rheumatoid arthritis.The Cell Surface Markers Expression in Postmenopausal Women and Relation to Obesity and Bone Status.NFAT2 is an essential mediator of orthopedic particle-induced osteoclastogenesis.Mediators of inflammation-induced bone damage in arthritis and their control by herbal products1,25-dihydroxyvitamin D3 inhibits the RANKL pathway and impacts on the production of pathway-associated cytokines in early rheumatoid arthritis.CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.Senescent T-Cells Promote Bone Loss in Rheumatoid Arthritis.RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
P2860
Q24799036-5E8B7118-15B5-4E05-8166-5DBD4A2D98B1Q24812326-43DCAAE2-59BE-4A50-B33C-13A5759AA4F8Q26796458-C6EE9C32-AEA0-4015-AAAD-77E60906555CQ27329714-DC39F041-1A1B-4691-AA3A-EDD486F27DA4Q28385908-87BDAF66-4A13-4F7D-98A6-049E2B31289FQ28576330-F42443AB-4935-4212-8361-084AAF850EF9Q30540259-099EDE5D-40EB-4194-99BA-EB71FD30BABCQ33631498-EAAAF0F5-4195-4820-912E-DB0B0DDF4726Q33692037-1EDB78D0-A5F5-4DD7-B847-2F70F118AF00Q33875771-BAEE3DF3-0A35-462C-B3FB-0D73CAC957F4Q34108110-F1272169-5DD5-4E51-B537-EA4AFCA6034CQ34152929-B4D5907F-7B1B-4644-941C-1D9678C27348Q34171862-69C9818D-763D-459E-A725-469E0699C41EQ35165886-9F0F5D0F-8EE0-4D6F-A8CC-D32AAD7E39A4Q35553437-7C85942A-E29F-4C2E-9CC8-5E003A250739Q35553467-4C2D76D5-F606-476C-A576-95FCCFB7571EQ35612713-41D1F5CE-7486-41AC-B8B5-835134A24D33Q36078749-6D642FB5-E136-4C28-A010-57D657ED2457Q36414215-AF4C9349-697A-4A5F-9A8C-B865CA298D19Q36610276-9FE567BD-D5B9-42C5-9E58-D48123BD291AQ36867041-4F443840-1922-4985-9315-8F51E75021C2Q37108817-1F4A0A91-0A93-4B5B-A67B-46A65C76E05FQ37224687-5345A11B-8262-4017-B592-A12B7F1287D2Q37288057-26895F03-8BC8-4BB3-B341-E6730C9F2FA7Q37397881-7505766C-E8B3-4A1C-BD89-A5D10ED7962CQ39333539-1C3BCA46-D171-4D56-9F69-76E27095F457Q41338463-2A923F14-B973-42BB-881D-EE689A19DACDQ41827067-04A67CB0-6708-4088-ABF0-BDD7859055E5Q41922030-D762629B-A612-4205-9AE7-E9F459CCC515Q42110909-45289CDF-EFEC-40A8-AD56-7DD0FD853B36Q42586718-F2D52936-5546-45C1-BDC8-A2ABDD46C248Q50234923-E028EE8E-6C5E-4FA2-A33B-BDB84946CD7FQ56892940-47433FB6-FBEB-4CDC-B18C-DCD28997E33F
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Role of RANKL and RANK in bone loss and arthritis.
@ast
Role of RANKL and RANK in bone loss and arthritis.
@en
Role of RANKL and RANK in bone loss and arthritis.
@nl
type
label
Role of RANKL and RANK in bone loss and arthritis.
@ast
Role of RANKL and RANK in bone loss and arthritis.
@en
Role of RANKL and RANK in bone loss and arthritis.
@nl
prefLabel
Role of RANKL and RANK in bone loss and arthritis.
@ast
Role of RANKL and RANK in bone loss and arthritis.
@en
Role of RANKL and RANK in bone loss and arthritis.
@nl
P2093
P2860
P1476
Role of RANKL and RANK in bone loss and arthritis
@en
P2093
D Holstead Jones
J M Penninger
P2860
P304
P356
10.1136/ARD.61.SUPPL_2.II32
P407
P478
61 Suppl 2
P577
2002-11-01T00:00:00Z